Skip to content

The Effect of Aerobic Exercise on Lower Urinary System Symptoms in Women With Diabetes Mellitus

The Effect Of Aerobic Exercise On Bladder Function And Lower Urinary Tract Symptoms In Women Who Has Diabetes Mellitus With Lower Urinary Tract Symptoms

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06249399
Enrollment
44
Registered
2024-02-08
Start date
2023-05-03
Completion date
2024-03-01
Last updated
2024-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2, Lower Urinary Tract Symptoms

Keywords

Lower urinary tract symptoms, Diabetes Mellitus, Type 2, bladder, aerobic exercise, quality of life

Brief summary

The goal of this clinical trial is to investigate the effect of aerobic exercise (AE) on bladder functions and urinary system symptoms in women diagnosed with Diabetes Mellitus (DM) and suffered from Lower Urinary Tract Symptoms (LUTS). In the study, 44 individuals (35-55 age) were divided into two groups: Aerobic Exercise (AE) (n=22) and Control Group (n=22) by simple random method. The main questions it aims to answer are: * Is aerobic exercise effective on bladder functions in women diagnosed with Diabetes Mellitus and suffered from Lower Urinary Tract Symptoms? * Is aerobic exercise effective on urinary tract symptoms in women diagnosed with Diabetes Mellitus and suffered from Lower Urinary Tract Symptoms? * Is aerobic exercise effective on quality of life in women diagnosed with Diabetes Mellitus and suffered from Lower Urinary Tract Symptoms? Intervention/treatment * Control group individuals will be given a behavioral treatment program. * Submaximal aerobic exercise training will be given to the AE group in addition to the behavioral treatment program.

Detailed description

The goal of this clinical trial is to investigate the effect of aerobic exercise (AE) on bladder functions and urinary system symptoms in women diagnosed with Diabetes Mellitus (DM) and suffered from Lower Urinary Tract Symptoms (LUTS). In the study, 44 individuals (35-55 age) were divided into two groups: Aerobic Exercise (AE) (n=22) and Control Group (n=22) by simple random method. Bladder sensation (first sensation) and compliance from urodynamic evaluations will be taken as reference as the primary outcome measurement in treatment effectiveness. * Control group individuals will be given a behavioral treatment program. * Submaximal aerobic exercise training will be given to the AE group in addition to the behavioral treatment program. AE training was provided three days a week, 45 minutes a day, for 12 weeks. The behavioral treatment protocol was completed with an initial training period of 40 minutes, and subsequent control interviews of 20 minutes at four-week intervals.

Interventions

OTHERAerobic Exercise

Aerobic Exercise training will be provided three days a week, 45 minutes a day, for 12 weeks. Patients will be subjected to submaximal aerobic exercise with rhythmic movements without equipment via video conference accompanied by a physiotherapist.

BEHAVIORALBehavioral Treatment Program

Behavioral Treatment Program will be completed with an initial training period of 40 minutes, and subsequent control interviews of 20 minutes at four-week intervals.

Sponsors

University of Gaziantep
CollaboratorOTHER
Hasan Kalyoncu University
CollaboratorOTHER
Gaziantep Islam Science and Technology University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Two groups: aerobic exercise group and control group.

Eligibility

Sex/Gender
FEMALE
Age
35 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Women between the ages of 35-55, * Individuals who volunteer to participate in the study, * Those diagnosed with Type II diabetes for 5 years or more and those diagnosed with LUTS

Exclusion criteria

* Stage 2 and more advanced pelvic organ prolapse, * Urinary tract infection, * Has had previous surgery for urinary incontinence and pelvic organ prolapse, * Diagnosis of Cerebro Vascular Event (CVE) and dementia, * Using A-blockers, antimuscarinics, antidepressants, diuretics and antihistamines, * Individuals in menopause.

Design outcomes

Primary

MeasureTime frameDescription
Bladder Compliance10 minutes (Change from Baseline at 12 weeks)Bladder compliance will be evaluated by urodynamics. With urodynamic evaluations, pathologies of the lower urinary system can be diagnosed and classified. Urodynamic examinations are performed in a suitable laboratory environment. First of all, a suitable sterile catheter is placed in the bladder and isotonic fluid is filled into it at a certain speed. In this way, the behavior of the bladder and its muscles during urine filling, pressure measurements and behavior during urination are examined. Bladder functions are evaluated with urodynamic evaluations. With the urodynamic evaluation will be performed by the clinician in the urology outpatient clinic compliance (ml/cmH2O) will be recorded.
Bladder Sensation10 minutes (Change from Baseline at 12 weeks)Bladder sensation will be evaluated by urodynamics. With urodynamic evaluations, pathologies of the lower urinary system can be diagnosed and classified. Urodynamic examinations are performed in a suitable laboratory environment. First of all, a suitable sterile catheter is placed in the bladder and isotonic fluid is filled into it at a certain speed. In this way, the behavior of the bladder and its muscles during urine filling, pressure measurements and behavior during urination are examined. Bladder functions are evaluated with urodynamic evaluations. With the urodynamic evaluation will be performed by the clinician in the urology outpatient clinic sensation (ml) will be recorded.

Secondary

MeasureTime frameDescription
Maximum Bladder Capacity10 minutes (Change from Baseline at 12 weeks)Maximum bladder capacity will be evaluated by urodynamics. Urodynamic examinations are performed in a suitable laboratory environment. First of all, a suitable sterile catheter is placed in the bladder and isotonic fluid is filled into it at a certain speed. In this way, the behavior of the bladder and its muscles during urine filling, pressure measurements and behavior during urination are examined. Bladder functions are evaluated with urodynamic evaluations. With the urodynamic evaluation will be performed by the clinician in the urology outpatient clinic Maximum bladder capacity (ml) will be recorded.
Urine Maximum Flow Rate10 minutes (Change from Baseline at 12 weeks)Urine maximum flow rate will be evaluated by urodynamics. Urodynamic examinations are performed in a suitable laboratory environment. First of all, a suitable sterile catheter is placed in the bladder and isotonic fluid is filled into it at a certain speed. In this way, the behavior of the bladder and its muscles during urine filling, pressure measurements and behavior during urination are examined. Bladder functions are evaluated with urodynamic evaluations. With the urodynamic evaluation will be performed by the clinician in the urology outpatient clinic Maximum flow rate (ml/s) will be recorded.
Bladder Residual Volume10 minutes (Change from Baseline at 12 weeks)Bladder residual volume rate will be evaluated by urodynamics. Urodynamic examinations are performed in a suitable laboratory environment. First of all, a suitable sterile catheter is placed in the bladder and isotonic fluid is filled into it at a certain speed. In this way, the behavior of the bladder and its muscles during urine filling, pressure measurements and behavior during urination are examined. Bladder functions are evaluated with urodynamic evaluations. With the urodynamic evaluation will be performed by the clinician in the urology outpatient clinic Residual volume (cc) will be recorded.
Ultrasonography (USG) evaluation10 minutes (Change from Baseline at 12 weeks)Ultrasonography will be performed by the doctor using the measured thickest part of the bladder wall as reference. The wall thickness of the bladder (mm) will be noted when the bladder is empty and full. USG is a non-invasive imaging method that physicians routinely use to evaluate the urinary system.
Voiding Volume10 minutes (Change from Baseline at 12 weeks)Voiding volume will be evaluated by urodynamics. Urodynamic examinations are performed in a suitable laboratory environment. First of all, a suitable sterile catheter is placed in the bladder and isotonic fluid is filled into it at a certain speed. In this way, the behavior of the bladder and its muscles during urine filling, pressure measurements and behavior during urination are examined. Bladder functions are evaluated with urodynamic evaluations. With the urodynamic evaluation will be performed by the clinician in the urology outpatient clinic Voiding volume (ml) will be recorded.
King's Health Questionnaire (KHQ)Change from Baseline at 12 weeksIt will be used to evaluate urinary system symptom severity and quality of life related to urinary system symptoms.The KHQ scale consists of two parts and 32 items. In the first part, there are two single-item questions about general health and quality of life. Again, in the first part, it consists of seven subheadings consisting of multiple items, including the individual's roles in daily life, physical condition, social situation, personal relationships, emotional problems, sleep/energy disorders, and violence measurements, and consists of 21 questions. The second part is a scale consisting of 11 questions that questions the presence of lower urinary tract symptoms and the severity of symptoms.Scoring on the Symptom Severity Scale ranges from 0 points (best) to 30 points (worst). In other KHQ subheadings, the scale scoring is 0 points (best) -100 points (worst). An increase in the score obtained from KHQ indicates a decrease in the quality of life.
Bristol Female Lower Urinary System Symptom Index (BFLUSSI)Change from Baseline at 12 weeksIt will be used to evaluate the Quality of Life Due to Lower Urinary System Symptoms.This scale includes storage functions (questions 1-4), excretory functions (questions 5-7), urinary incontinence (questions 8-12), sexual life (questions 13-14) and quality of life (questions 15-19). It consists of five sections with subheadings. The highest score that can be obtained from the survey is 71, while the lowest score is 0. A high score from the survey indicates that the severity of LUTS is high and sexual functions and quality of life are negatively affected.
HbA1cChange from Baseline at 12 weeksHbA1c (blood glucose level) will be noted as a result of the blood evaluations taken by the clinician.
Patient Information FormChange from Baseline at 12 weeksPatient information such as sociodemographic (age (year), occupation (employed/unemployed), education (literate/primary school/high school/university/graduate school), marital status (married/single), number of births (n), type of delivery (vaginal/caesarean section) and physical (height (m), weight (kg), BMI (kg/m2),constipation (, type 2 DM duration (year)) will be noted. Personal habits (liquid consumption habits (ml), number of urinations per day (n)) will be noted.
Bladder DiaryChange from Baseline at 12 weeks48-hour bladder diary will be taken. The average of daily urination frequency numbers and daily fluid consumption amounts will be taken.
Voiding Time10 minutes (Change from Baseline at 12 weeks)Voiding time will be evaluated by urodynamics. Urodynamic examinations are performed in a suitable laboratory environment. First of all, a suitable sterile catheter is placed in the bladder and isotonic fluid is filled into it at a certain speed. In this way, the behavior of the bladder and its muscles during urine filling, pressure measurements and behavior during urination are examined. Bladder functions are evaluated with urodynamic evaluations. With the urodynamic evaluation will be performed by the clinician in the urology outpatient clinic Voiding time (sec) will be recorded.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 20, 2026